Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for AC Immune (ACIU : NSDQ)

• Company Description    AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland. Number of Employees: 172

• Price / Volume Information    Yesterday's Closing Price: $3.30 Daily Weekly Monthly 20 Day Moving Average: 402,882 shares Shares Outstanding: 100.41 (millions) Market Capitalization: $331.35 (millions) Beta: 1.58 52 Week High: $4.00 52 Week Low: $1.43 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -7.04% -9.48% 12 Week 54.93% 48.51% Year To Date 22.22% 6.83%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL EPFL INNOVATION PARK BUILDING B - LAUSANNE,V8 1015 CHE ph: 41-21-345-9121 fax: 41-21-345-9120 ir@acimmune.com http://www.acimmune.com

• General Corporate Information    Officers Andrea Pfeifer - Chief Executive Officer Douglas Williams - Chair and Director Monika Butler - Vice Chair and Director Piergiorgio Donati - Chief Operations Officer Christopher Roberts - Chief Financial Officer Peer Information AC Immune (CORR.) AC Immune (RSPI) AC Immune (CGXP) AC Immune (BGEN) AC Immune (GTBP) AC Immune (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: H00263105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/12/26 Share - Related Items Shares Outstanding: 100.41 Most Recent Split Date: (:1) Beta: 1.58 Market Capitalization: $331.35 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.19 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.86 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.25 Price/Cash Flow: - Price / Sales: 64.30 EPS Growth vs. Year Ago Period: -433.33% vs. Previous Quarter: 20.00% Sales Growth vs. Year Ago Period: -96.01% vs. Previous Quarter: -25.79% ROE 09/30/25 - -84.32 06/30/25 - -49.35 03/31/25 - -44.60 ROA 09/30/25 - -35.94 06/30/25 - -23.16 03/31/25 - -22.25 Current Ratio 09/30/25 - 1.16 06/30/25 - 1.33 03/31/25 - 1.53 Quick Ratio 09/30/25 - 1.16 06/30/25 - 1.33 03/31/25 - 1.53 Operating Margin 09/30/25 - -1,642.89 06/30/25 - -174.94 03/31/25 - -177.79 Net Margin 09/30/25 - -1,642.89 06/30/25 - -174.94 03/31/25 - -177.79 Pre-Tax Margin 09/30/25 - -1,654.86 06/30/25 - -176.80 03/31/25 - -179.67 Book Value 09/30/25 - 0.78 06/30/25 - 0.90 03/31/25 - 1.05 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©